Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
15081
Beskrivning
Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02254005
Länk
https://clinicaltrials.gov/show/NCT02254005
Nyckelord
Versioner (3)
- 2016-05-15 2016-05-15 -
- 2016-06-18 2016-06-18 -
- 2016-06-18 2016-06-18 -
Uppladdad den
15 maj 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Neoplasms NCT02254005
Eligibility Breast Neoplasms NCT02254005
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT02254005
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
1. female patients aged 18 years or older
boolean
C0001779 (UMLS CUI [1,1])
C0079399 (UMLS CUI [1,2])
C0079399 (UMLS CUI [1,2])
ID.2
Item
2. patients with breast cancer positive for cd44v6 in at least 50 % of the tumour cells
boolean
C0675853 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
C1446409 (UMLS CUI [1,2])
ID.3
Item
3. patients with metastases pretreated with anthracyclines and taxanes (unless contraindications to taxanes and / or anthracyclines) or not amenable to established treatments
boolean
C2709094 (UMLS CUI [1,1])
C0282564|C3541958 (UMLS CUI [1,2])
C0282564|C3541958 (UMLS CUI [1,2])
ID.4
Item
4. measurable tumour deposits by one or more radiological techniques (mri, ct)
boolean
C0006826 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C1513040 (UMLS CUI [1,2])
ID.5
Item
5. life expectancy of at least 6 months
boolean
C0023671 (UMLS CUI [1])
ID.6
Item
6. eastern cooperative oncology group (ecog) performance score ≤ 2
boolean
C1520224 (UMLS CUI [1])
ID.7
Item
7. patients must have given written informed consent (which must be consistent with international conference on harmonisation-good clinical practice (ich-gcp) and local legislation)
boolean
C0021430 (UMLS CUI [1])
ID.8
Item
1. hypersensitivity to humanised or murine antibodies, immunoconjugates or the excipients of the trial drugs
boolean
C0020517 (UMLS CUI [1,1])
C0003241|C0243020|C0015237 (UMLS CUI [1,2])
C0003241|C0243020|C0015237 (UMLS CUI [1,2])
ID.9
Item
2. known secondary malignancy requiring therapy
boolean
C3266877 (UMLS CUI [1])
ID.10
Item
3. active infectious disease
boolean
C0009450 (UMLS CUI [1])
ID.11
Item
4. brain metastases requiring therapy
boolean
C0220650 (UMLS CUI [1])
ID.12
Item
5. neuropathy common toxicity criteria (ctc) grade 2 or above
boolean
C1516728 (UMLS CUI [1])
ID.13
Item
6. absolute neutrophil count less than 1,500/mm3
boolean
C0200633 (UMLS CUI [1])
ID.14
Item
7. platelet count less than 100,000/mm3
boolean
C0005821 (UMLS CUI [1])
ID.15
Item
8. bilirubin greater than 1.5 mg/dl (> 26 μmol/l, système internationale (si) unit equivalent)
boolean
C1278039 (UMLS CUI [1])
ID.16
Item
9. aspartate amino transferase (ast) and/or alanine amino transferase (alt) greater than 3 times the upper limit of normal
boolean
C0004002 (UMLS CUI [1,1])
C0001899 (UMLS CUI [1,2])
C1519815 (UMLS CUI [1,3])
C0001899 (UMLS CUI [1,2])
C1519815 (UMLS CUI [1,3])
ID.17
Item
10. serum creatinine greater than 1.5 mg/dl (> 132 μmol/l, si unit equivalent)
boolean
C0201976 (UMLS CUI [1])
ID.18
Item
11. concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
boolean
C0201976 (UMLS CUI [1])
ID.19
Item
12. chemo- or immunotherapy within the past four weeks prior to treatment with the trial drug or during the trial (except for present trial drug)
boolean
C1514457|C1514461 (UMLS CUI [1])
ID.20
Item
13. radiotherapy to breast and thorax region within the past four weeks before inclusion or during the trial
boolean
C1522449 (UMLS CUI [1,1])
C3828653 (UMLS CUI [1,2])
C3828653 (UMLS CUI [1,2])
ID.21
Item
14. women who are sexually active and unwilling to use a medically acceptable method of contraception
boolean
C0241028 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,2])
ID.22
Item
15. pregnancy or lactation
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
ID.23
Item
16. treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
boolean
C2348568 (UMLS CUI [1])
ID.24
Item
17. patients unable to comply with the protocol
boolean
C1321605 (UMLS CUI [1])